According to
Maccabi, only 31 people out of 163,000 fully vaccinated customers became infected 7-16 days following their second shot. A control group of similar ages had over 6,500 infections in the same period. The two groups are not perfectly comparable – those who get vaccinated may be more concerned about COVID-19 and likely to take other precautions, for example. Nevertheless, it takes a lot to explain away a 200-fold difference in infection rates. Maccabi told the
Times of Israel the vaccine was 92 percent effective, only slightly below the 95 percent reported in clinical trials. That's particularly impressive since the Maccabi sample was much older on average than Pfizer's test population.
The health ministry's sample is larger, and the results almost as good. Within a week of their second vaccination, 317 people out of 715,425 tested positive for SARS-CoV-2, a rate of 0.04 percent. It's harder for clinical trials to measure rare events like hospitalizations and deaths than infections, so it's particularly important that Israel reported just 16 hospital cases among the vaccinated, or 0.002 percent.
However, the Israeli data is less positive for the benefits of a single Pfizer/BioNtech dose, possibly explaining why Israel's national infection rate kept climbing even after a larger proportion received their first round. At the time of writing, there are 404 critically ill patients in Israeli hospitals who got their first vaccine dose prior to testing positive. This potentially conflicts with the
clinical trial data, which showed infection rates flatlining even before the second round was administered.